Futurechem Co., Ltd

Sogang University Research Foundation

Byoung-Se Lee

Dae-Yoon Chi

Chansoo Park

So-Young Chu

Woojin Cho

Jong-Min Kim

Heewon Kang

Jae-seung Kim

Jin-sook Ryu

Hee-Seup Kil

Seung-jun Oh

Dae-hyuk Moon

Hye-Rim Kwon

Kyunghun Kim

Cheol-Soo Lee

Eun-Young Heo

Sirion Uthaiwan

Jae-Hak Lee

Yu-Jin Bae

Woon-Jung Jung

Min-Hyung Lee

Hyojin Cha

The present invention relates to a solid precursor in the form of an organic salt, the solid precursor having a solid support, a method for manufacturing same, and an application thereof. The solid precursor of the present invention enables omission of the [F]fluoride refining process using additional cartridge, and the use of excessive phase-transfer catalyst, and can easily remove remaining substance after reaction through the solid support inside the precursor. The solid precursor of the present invention is very appropriate for an automated synthesis device as an all-in-one system that can carry out overall process of [F]fluorosis reaction, when used by charging in a cartridge.

Precursor compound connected to solid support for manufacturing 18F radiopharmaceutical, method for manufacturing same, and application thereof

The present invention relates to a precursor of positron emission tomography (PET) radioactive medical supplies, a preparation method thereof, and an application thereof, and more specifically, to a precursor having a tetravalent organic salt leaving group, a preparation method, and a method for preparing desired PET radioactive medical supplies in a high radiochemical yield within a short preparation time by introducingF using the same through a single step. The precursor having a tetravalent organic salt leaving group of the present invention can simplify the known complex multistep preparation of radioactive medical supplies into a single step, can save production costs because an excessive amount of a phase transfer catalyst is not required, facilitates separation of a compound after reaction, and enables rapid reaction velocity. The features are appropriate for the mass production of PET radioactive medical supplies by an automated synthesis system.

18F-labeled precursor of PET radioactive medical supplies, and preparation method thereof

Method and apparatus for synthesizing an F-18 labeled radioactive pharmaceutical by labeling a precursor with an F-18 radioactive isotope, by reacting the labeled precursor to obtain a labeled pharmaceutical, by separating impurities from the labeled pharmaceutical to provide a purified labeled pharmaceutical, and by collecting the purified labeled pharmaceutical. The apparatus includes a labeling cartridge that contains the precursor, receives the isotope, and causes a labeling reaction to provide the labeled precursor; a synthesizing container that receives the labeled precursor, receives at least one reagent effective to hydrolyze the labeled precursor, and within which the labeled precursor undergoes a hydrolysis reaction to provide the labeled pharmaceutical; and a separation cartridge that receives the labeled pharmaceutical, and contains a polymer compound that separates impurities into polar compounds and nonpolar compounds to provide the purified labeled pharmaceutical. The labeling and separation cartridges may be contained in a removable cassette.

Apparatus and method for synthesizing F-18 labeled radioactive pharmaceuticals

The present invention relates to (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or to the pharmaceutically acceptable salt thereof, to a method for preparing same, and to a pharmaceutical composition containing same as active ingredients for the diagnosis or treatment of neurodegenerative brain diseases. The aryl derivatives of the present invention are (3-fluoro-2-hydroxy)propyl-functionalized to increase the polarity thereof, and therefore the drugs containing the aryl derivatives can easily permeate into the cerebrovascular membrane, thus increasing the effectiveness of the drugs. As the aryl derivatives of the present invention strongly bind to &#x3b2;-amyloid, the aryl derivatives, when labeled with radioisotope, can be used as a diagnostic agent for non-invasively diagnosing early Alzheimer's disease. Further, the aryl derivatives of the present invention bind to low molecular &#x3b2;-amyloid peptide conjugates to inhibit the generation of malignant high molecular &#x3b2;-amyloid plaque, and thus can be effectively used as a therapeutic agent for neurodegenerative brain diseases such as Alzheimer's disease.

(3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for the diagnosis or treatment of neurodegenerative brain diseases

Growing community of inventors

Seoul, South Korea

Byoung-Se Lee